GlassScriptPhysician profile
Saman Hasan
NPI 1871793893
$4,640.19
in general payments reported to CMS, 2019-2025
26 companies · $1,218 in 2025
The $1,218 reported for 2025 was more than what 84% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $299 · 2020: $145 · 2022: $1,047 · 2023: $1,028 · 2024: $904 · 2025: $1,218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,149.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $587.34 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $573.38 | 2019-2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $502.24 | 2022-2025 | Austedo Xr, Austedo Xr, Austedo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $420.88 | 2022-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $335.12 | 2019-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $297.08 | 2022-2025 | Hetlioz, Fanapt |
| Otsuka America Pharmaceutical, INC. | $240.99 | 2019-2025 | Rexulti |
| Lundbeck LLC | $231.92 | 2020-2025 | Rexulti |
| Bausch Health US, LLC | $206.66 | 2019-2025 | Aplenzin, Wellbutrin |
| Tris Pharma INC | $153.93 | 2022-2024 | Dyanavel Xr |
| Idorsia Pharmaceuticals US INC | $143.33 | 2022-2024 | Quviviq |
| Merck Sharp & Dohme LLC | $118.11 | 2022-2023 | Belsomra |
| Axsome Therapeutics, INC. | $116.77 | 2023-2025 | Auvelity |
| Alkermes, INC. | $105.54 | 2022-2023 | Aristada, Lybalvi |
| Neos Therapeutics, LP | $95.44 | 2019-2024 | Adzenys Xr-Odt |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $82.24 | 2022-2023 | Spravato |
| Corium, LLC | $79.75 | 2022-2024 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $73.66 | 2024-2025 | Cobenfy |
| Supernus Pharmaceuticals, INC. | $65.92 | 2022-2023 | Qelbree |
| Shire North American Group INC | $54.86 | 2019 | |
| Noven Therapeutics, LLC | $33.73 | 2023 | Xelstrym |
| Neuronetics, INC. | $32.54 | 2019-2020 | |
| Allergan, INC. | $31.84 | 2019 | |
| Brainsway USA INC | $19.31 | 2022 | |
| Sunovion Pharmaceuticals INC. | $18.98 | 2022 | |
| Collegium Pharmaceutical, INC. | $18.63 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saman Hasan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.